 | Up a level |
Bargagli, Matteo; Liguori, Antonio; Napodano, Cecilia; Baroni, Silvia; Tomasello, Lidia; Pizzolante, Fabrizio; De Matthaeis, Nicoletta; De Ninno, Grazia; Grieco, Antonio; Gasbarrini, Antonio; Gambaro, Giovanni; Ferraro, Pietro Manuel; Miele, Luca (2023). Urinary lithogenic profile of patients with non-alcoholic fatty liver disease. Nephrology, dialysis, transplantation, 38(11), pp. 2652-2654. Oxford University Press 10.1093/ndt/gfad106
Bargagli, Matteo; Vetsch, Andri; Anderegg, Manuel A; Dhayat, Nasser A; Huynh-Do, Uyen; Faller, Nicolas; Vogt, Bruno; Ferraro, Pietro Manuel; Fuster, Daniel G (2023). Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients. Nephrology, dialysis, transplantation, 38(7), pp. 1645-1654. Oxford University Press 10.1093/ndt/gfac298
Ferraro, Pietro Manuel; Bargagli, Matteo; Faller, Nicolas; Anderegg, Manuel A; Huynh-Do, Uyen; Vogt, Bruno; Gambaro, Giovanni; Fuster, Daniel G (2023). The role of urinary supersaturations for lithogenic salts in the progression of autosomal dominant polycystic kidney disease. Journal of nephrology JN, 36(4), pp. 1011-1018. Wichtig Editore 10.1007/s40620-022-01540-5
Ferraro, Pietro Manuel; Fuster, Daniel Guido (2021). Clinical physiology of the kidney, electrolytes and lithiasis. The “old” meets the “new”. Journal of nephrology JN, 34(1), pp. 29-30. Springer 10.1007/s40620-020-00850-w
Williams, James C; Gambaro, Giovanni; Rodgers, Allen; Asplin, John; Bonny, Olivier; Costa-Bauzá, Antonia; Ferraro, Pietro Manuel; Fogazzi, Giovanni; Fuster, Daniel G.; Goldfarb, David S; Grases, Félix; Heilberg, Ita P; Kok, Dik; Letavernier, Emmanuel; Lippi, Giuseppe; Marangella, Martino; Nouvenne, Antonio; Petrarulo, Michele; Siener, Roswitha; Tiselius, Hans-Göran; ... (2021). Urine and stone analysis for the investigation of the renal stone former: a consensus conference. Urolithiasis, 49(1), pp. 1-16. Springer 10.1007/s00240-020-01217-3
Bargagli, Matteo; Ferraro, Pietro Manuel; Dhayat, Nasser; Anderegg, Manuel; Fuster, Daniel (2021). Effect of Tolvaptan treatment on acid-base homeostasis in ADPKD patients. Kidney international reports, 6(6), p. 1749. Elsevier 10.1016/j.ekir.2021.04.012
Bargagli, Matteo; Dhayat, Nasser A.; Anderegg, Manuel; Semmo, Mariam; Huynh-Do, Uyen; Vogt, Bruno; Ferraro, Pietro Manuel; Fuster, Daniel G. (2020). Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan. Clinical Journal of the American Society of Nephrology, 15(7), pp. 1007-1014. American Society of Nephrology 10.2215/CJN.13861119
Ferraro, Pietro Manuel; Arrabal-Polo, Miguel Ángel; Capasso, Giovambattista; Croppi, Emanuele; Cupisti, Adamasco; Ernandez, Thomas; Fuster, Daniel Guido; Galan, Juan Antonio; Grases, Felix; Hoorn, Ewout J; Knauf, Felix; Letavernier, Emmanuel; Mohebbi, Nilufar; Moochhala, Shabbir; Petkova, Kremena; Pozdzik, Agnieszka; Sayer, John; Seitz, Christian; Strazzullo, Pasquale; Trinchieri, Alberto; ... (2019). A preliminary survey of practice patterns across several European kidney stone centers and a call for action in developing shared practice. Urolithiasis, 47(3), pp. 219-224. Springer 10.1007/s00240-019-01119-z
Gambaro, Giovanni; Croppi, Emanuele; Coe, Fredric; Lingeman, James; Moe, Orson; Worcester, Elen; Buchholz, Noor; Bushinsky, David; Curhan, Gary C; Ferraro, Pietro Manuel; Fuster, Daniel Guido; Goldfarb, David S; Heilberg, Ita Pfeferman; Hess, Bernard; Lieske, John; Marangella, Martino; Milliner, Dawn; Preminger, Glen M; Reis Santos, Jose' Manuel; Sakhaee, Khashayar; ... (2016). Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. Journal of nephrology JN, 29(6), pp. 715-734. Springer 10.1007/s40620-016-0329-y
